ψαμιξιγ 15 ξ"β

φεψϊ ξϊο

PER OS

ξιπεο

Capsules

ωιξεω αϊψετδ

REVLIMID is indicated for 1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.3. Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

ξρτψ ψιωεν

140 47 31662 14

ιφψο

Celgene Europe Ltd, Uk

ϊεχσ ψιωιεο μϊψετδ

04/2014 - 04/2024

• δηξψδ μςμεο
• ςμεο μφψλο
• ςμεο μψετΰ

δερτϊ ϊβεαδ ηγωδ ων * λεϊψϊ * ςζεψ μπε μεεγΰ ωΰϊδ μΰ ψεαεθ δϊβεαδ ωμκ χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν   αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.